- Price
- $82.07
- Day
- +2.64%
- Mkt Cap
- $16.07B
- 52W Range
- $42.09 – $93.42
- Volume
- 1.66M
- Beta
- 0.95
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 23.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,703 shares of the company's stock after acquiring an additional 31,797 shares during the quarter.
Read full article
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its second quarter 2026 financial results and business update after the market closes on Monday, August 10, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
Read full article
Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year.
Read full article
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Affinity Asset Advisors LLC cut its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 53.1% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company's stock after selling 170,000 shares during the quarter.
Read full article
California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 21.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 253,479 shares of the company's stock after acquiring an additional 45,596 shares during the period. California Public Employees Retirement System
Read full article
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
Read full article
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockbuster opportunity for BridgeBio - Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biology without the need for calcium and vitamin D supplements, with a favorable safety and tolerability profile - BridgeBio is also currently enrolling CALIBRATE-PEDS, a registrational Phase 2/3 trial to study encaleret in pediatric ADH1 and intends to initiate the RECLAIM-HP Phase 3 registrational study of encaleret in chronic hypoparathyroidism later this summer; successful development could extend encaleret's utility to a broader patient population PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1).
Read full article
Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 10.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 889,356 shares of the company's stock after selling 104,864 shares during the quarter. Allspring Global Investments Holdings
Read full article